Temple Health Launches New Fox Chase-Temple Urologic Institute

Fox Chase Cancer Center and Temple Health are pleased to announce the new Fox Chase-Temple Urologic Institute, a groundbreaking initiative that will concentrate on both benign and oncologic urology. With over 20 urologists on faculty, the Institute will provide services at multiple locations throughout the greater Philadelphia area.

“Our urologists have experience treating some of the most complex and advanced oncologic and benign urologic conditions. As leaders in the field, our urologists not only stay on top of the latest changes in medicine but often lead the development of new treatment advances and surgical techniques,” said Robert Uzzo, MD, MBA, FACS, President and CEO of Fox Chase Cancer Center and Executive Director of the Institute. The new Institute’s executive management team includes Alexander Kutikov, MD, FACS, Jack Mydlo, MD, MBA, Daniel Eun, MD, and Jay Simhan, MD, FACS.

Beyond general urologic care, the highly experienced benign urology team specializes in less common procedures such as advanced perineal and abdominal reconstruction, prostate enucleation, bladder augmentation and urinary diversion, complex bladder pathology, and vaginal reconstruction.

The Fox Chase-Temple Urologic Institute will offer patients access to cutting-edge clinical trials, targeted therapies, immunotherapies, and advanced radiation therapies for the treatment of urologic cancers. Its urologic oncologists will collaborate closely with renowned medical and radiation oncologists to take a multidisciplinary approach to treating cancer, including diagnosis, treatment, and follow-up care.

Meeting biweekly to discuss patient cases and potential treatment options, the Institute’s team will leverage their extensive experience as one of the largest fellowship-trained genitourinary cancer teams in the country.

The Fox Chase-Temple Urologic Institute is designed to provide a seamless transition for patients with urologic cancers who require treatment for benign urology conditions following cancer therapy. These services as well as many others will be offered at multiple locations, including Temple University Hospital - Main Campus, Fox Chase Cancer Center – Main Campus, Fox Chase - East Norriton, Temple Health - Center City, Temple Health - Fort Washington, Fox Chase - Huntingdon Pike, and Chestnut Hill Hospital, with ongoing plans to add providers and expand in response to growth.

“With the creation of this new urologic institute, Temple Health and Fox Chase will now be able to extend our exceptional, cutting-edge care to patients closer to their homes,” said Uzzo. “We are thrilled to extend these services to our neighboring communities and are committed to providing our patients with the quality and convenience they deserve from their healthcare providers.”